School of Medicine
Showing 21-40 of 300 Results
-
Afrin N. Kamal, MD MS
Clinical Assistant Professor, Medicine - Gastroenterology & Hepatology
BioAfrin Kamal is a board-certified gastroenterologist, who trained at Washington University in internal medicine, Cleveland Clinic in gastroenterology/hepatology, and most recently Stanford University in esophageal and motility diseases. Afrin shares a clinical passion in esophageal motility diseases with an an overlapping interest in health services and outcomes research.
-
Robin Kamal MD MBA
Associate Professor of Orthopaedic Surgery
Current Research and Scholarly InterestsWrist and Elbow Injuries and Quality Measures in Orthopaedic Surgery
-
Aya Kamaya, MD
Professor of Radiology (Body Imaging)
Current Research and Scholarly InterestsHepatobiliary imaging
Hepatocellular carcinoma
Urologic imaging
Gynecologic imaging
Thyroid imaging
Novel ultrasound technologies
Perfusion CT imaging of abdominal tumors -
Neeraja Kambham
Professor of Pathology
Current Research and Scholarly InterestsDr. Kambham's research interests primarily involve medical diseases and transplantation pathology of the kidney and liver.
-
Komal Kamra
Clinical Professor, Anesthesiology, Perioperative and Pain Medicine
Current Research and Scholarly InterestsPediatric Cardiac Anesthesia
Transesophageal Echocardiography
Adult Congenital Heart Disease
Clinical Informatics -
Kathleen Kan
Clinical Assistant Professor, Urology
BioDr. Kathleen Kan is a fellowship-trained pediatric urologist with a clinical practice based at LPCH and additional outreach programs in the South Bay. Her current practice includes general, endoscopic and complex reconstructive procedures and a clinical counseling interest in kidney stone disease and differences in sexual differentiation. She currently serves as the Associate Program Director of the Urology residency program.
Her current research is focused on understanding why health elementary schoolchildren develop new bladder and bowel problems. -
Matthew Kanan
Professor of Chemistry
BioAssociate Professor of Chemistry Matthew Kanan develops new catalysts and chemical reactions for applications in renewable energy conversion and CO2 utilization. His group at Stanford University has recently developed a novel method to create plastic from carbon dioxide and inedible plant material rather than petroleum products, and pioneered the study of “defect-rich” heterogeneous electro-catalysts for converting carbon dioxide and carbon monoxide to liquid fuel.
Matthew Kanan completed undergraduate study in chemistry at Rice University (B.A. 2000 Summa Cum Laude, Phi Beta Kappa). During doctoral research in organic chemistry at Harvard University (Ph.D. 2005), he developed a novel method for using DNA to discover new chemical reactions. He then moved into inorganic chemistry for his postdoctoral studies as a National Institutes of Health Postdoctoral Research Fellow at the Massachusetts Institute of Technology, where he discovered a water oxidation catalyst that operates in neutral water. He joined the Stanford Chemistry Department faculty in 2009 to continue research into energy-related catalysis and reactions. His research and teaching have already been recognized in selection as one of Chemistry & Engineering News’ first annual Talented 12, the Camille Dreyfus Teacher-Scholar Award, Eli Lilly New Faculty Award, and recognition as a Camille and Henry Dreyfus Environmental Mentor, among other honors.
The Kanan Lab addresses fundamental challenges in catalysis and synthesis with an emphasis on enabling new technologies for scalable CO2 utilization. The interdisciplinary effort spans organic synthesis, materials chemistry and electrochemistry.
One of the greatest challenges of the 21st century is to transition to an energy economy with ultra-low greenhouse gas emissions without compromising quality of life for a growing population. The Kanan Lab aims to help enable this transition by developing catalysts and chemical reactions that recycle CO2 into fuels and commodity chemicals using renewable energy sources. To be implemented on a substantial scale, these methods must ultimately be competitive with fossil fuels and petrochemicals. With this requirement in mind, the group focuses on the fundamental chemical challenge of making carbon–carbon (C–C) bonds because multi-carbon compounds have higher energy density, greater value, and more diverse applications that one-carbon compounds. Both electrochemical and chemical methods are being pursued. For electrochemical conversion, the group studies how defects known as grain boundaries can be exploited to improve CO2/CO electro-reduction catalysis. Recent work has unveiled quantitative correlations between grain boundaries and catalytic activity, establishing a new design principle for electrocatalysis, and developed grain boundary-rich copper catalysts with unparalleled activity for converting carbon monoxide to liquid fuel. For chemical CO2 conversion, the group is developing C–H carboxylation and CO2 hydrogenation reactions that are promoted by simple carbonate salts. These reactions provide a way to make C–C bonds between un-activated substrates and CO2 without resorting to energy-intensive and hazardous reagents. Among numerous applications, carbonate-promoted carboxylation enables the synthesis of a monomer used to make polyester plastic from CO2 and a feedstock derived from agricultural waste.
In addition to CO2 chemistry, the Kanan group is pursuing new strategies to control selectivity in molecular catalysis for fine chemical synthesis. Of particular interest in the use of electrostatic interactions to discriminate between competing reaction pathways based on their charge distributions. This effort uses ion pairing or interfaces to control the local electrostatic environment in which a reaction takes place. The group has recently shown that local electric fields can control regioselectivity in isomerization reactions catalyzed by gold complexes. -
Beverley Kane
Adjunct Clinical Assistant Professor, Medicine - Primary Care and Population Health
BioBeverley Kane, MD, was Board Certified in Family Medicine, then completed fellowships in Ob-Gyn (San Francisco Children's Hosptial) and Sports Medicine (London Univeristy). She has worked in the private practice of sports medicine; in medical informatics, specializing in doctor-patient communication (WebMD); and in stress management with her private practice, Horsensei Equine-Assisted Learning & THerapy (HEALTH). Her latest book, "Equine-imity--Stress Reduction and Emotional Self-Regulation in the Company of Horses," published 27 March 2021, can be seen at http://equine-imity.com/
-
Guson Kang
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Kang is an interventional cardiologist who specializes in the treatment of structural heart disease. He has expertise in complex coronary interventions, transcatheter aortic and mitral valve replacements, transcatheter mitral valve repair, left atrial appendage occlusion, PFO/septal defect closure, alcohol septal ablation, and paravalvular leak closure.
A Bay Area native, he graduated from Stanford University and obtained his medical degree at Yale University. He came back to Stanford to train in internal medicine, cardiology, and interventional cardiology before completing an advanced structural interventions fellowship at Ford Hospital. -
Ming Jeffrey Kao, PhD, MD
Clinical Associate Professor, Anesthesiology, Perioperative and Pain Medicine
Current Research and Scholarly Interests1. Patient-reported outcomes. Efficient, multi-feature item-response theory (IRT) based computerized adaptive testing (CAT) algorithm using item banks from PROMIS and NIH Toolbox
2. Activity monitoring. Novel analytic framework for physical activity monitoring in the context of pain.
3. Operations research. Multi-variable discrete and continuous optimization for Lean Hospital Management
4. National trends in pain medication prescription -
Peter Kao
Associate Professor of Medicine (Pulmonary and Critical Care Medicine)
Current Research and Scholarly InterestsOur research program has several active projects:
1.) Pulmonary Vascular Disease Simvastatin reversed experimental pulmonary hypertension, and is safe for treatment of patients. Blinded clinical trials of efficacy are in progress.
2.) Lung inflammation and regeneration (stem cells)
3.) Lung surfactant rheology and oxidative stress
4.) Gene regulation by RNA binding proteins, NF45 and NF90 through transcriptional and posttranscriptional mechanisms -
Michael S. Kapiloff, MD, PhD
Reinhard Family Professor, Professor (Research) of Ophthalmology and, by courtesy, of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsDr. Michael S. Kapiloff is a faculty member in the Departments of Ophthalmology and Medicine (Cardiovascular Medicine) and a member of the Stanford Cardiovascular Institute. Although Dr. Kapiloff was at one time a Board-Certified General Pediatrician, he is currently involved in full-time basic science and translational research. His laboratory studies the basic molecular mechanisms underlying the response of the retinal ganglion cell and cardiac myocyte to disease. The longstanding interest of his laboratory is the role in intracellular signal transduction of multimolecular complexes organized by scaffold proteins. Recently, his lab has also been involved in the translation of these concepts into new therapies, including the development of new AAV gene therapy biologics for the prevention and treatment of heart failure and for neuroprotection in the eye.
URL to NCBI listing of all published works:
http://www.ncbi.nlm.nih.gov/sites/myncbi/michael.kapiloff.1/bibliography/40252285/public/?sort=date&direction=descending
For more information see Dr. Kapiloff's lab website: http://med.stanford.edu/kapilofflab.html
